An interventional study of iTalkBetter Trained Items and iTalkBetter Untrained Items in Stroke, Aphasia and Anomia, sponsored by University College, London. Completed at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by University College, London · Not applicable, Interventional, and Treatment
iTALKBetter will provide an app-based therapy for people with word retrieval difficulties who have had a stroke.
This study aims to test the therapy application for people with naming difficulties through a small scale item-randomized controlled trial.
Mortality from stroke in the UK has reduced from 21% in 1999 to 12% in 2008. However, stroke prevalence has been increasing, the consequence of socioeconomic and scientific advances that have improved survival; which means that more people are surviving with long-standing disability. Language impairment (aphasia) is the second most common major impairment after stroke, with a prevalence of 250,000 in the UK. Aphasia may respond to therapy many months and years after the stroke occurs, but provision of specialist therapy (speech and language therapy - SALT) is far below that needed to provide optimal rehabilitation.
The investigators will address this by targeting a common symptom of post-stroke aphasia: impaired word retrieval problems. This is particularly important in patients receiving rehabilitation for associated disabilities as poor speech production can impair participation/compliance with treatment programmes. The study is designed to improve word retrieval in patients with post-stroke aphasia, who are in the chronic phase (>6 months post-stroke).
The main aim is to test the clinical efficacy of a novel, web-based, DNI. iTALKbetter will provide an effective training tool that patients can use to practice independently. This will free-up SALT time to provide additional assessment, supervision and functional intervention in a highly cost effective manner.
iTALKbetter will provide an app-based therapy for people with word retrieval difficulties who have had a stroke (naming app for a wide variety of common words and phrases).
This Digital Neuro Intervention (DNI) will provide the opportunity for the necessary increased rehabilitation to help people recover lost naming function. This will alleviate NHS Speech and Language Therapist (SALT) time and put users in control of when and where they carry out practice-based language therapy.
Purpose iTALKbetter will provide an app-based therapy for people with word retrieval difficulties who have had a stroke (naming app for a wide variety of common words and phrases).
What does it do? The DNI works via mass practice and feedback to the users on a trial-by-trial basis. The DNI is very simple in a way; it just presents a long series of pictures for users to name. The DNI will use speech recognition (SR) software in order to make a binary decision as to whether the user said the correct word or not. This affects what the next trial (object to name) is and what auditory cue (if any) is provided the next time the user has to name the same item.
What is the clinical trial design? A small, well-defined sample of patients with the potential to benefit from the DNI will be recruited. The main outcome measure is whether the DNI is effective at improving naming impairments on trained vs. untrained items. This comparison is within-subject and is achieved by comparing post-therapy measures to multiple baseline measures.
Outcome measures will be collected by the research team using a variety of standardized and non-standardized tests of language and cognition. These outcome measures are not built into the DNI at this point.
The DNI will be introduced to the participant when attending a testing session. One of the research team will explain how to use the DNI, provide instructions for the user, and give some time for practice items. When confident that the participant can use the DNI independently, the participant will take the device home and continue their therapy (suggested therapy time is 5-10 hours per week) which will be simultaneously monitored by the research team. The research team will also check in on the participant weekly to trouble shoot any difficulties they may have (whether motivational or technical). When the participant has completed the therapy block, they will be invited in again for testing and they will return the mobile device with the DNI on it. The participants who continue to receive standard care during the therapy block will be asked to record and submit details to the research team
Why is the research considered worth doing? Standard (face to face) Speech and Language Therapy (SALT) has a huge evidence-base but patients in the NHS have unmet therapy needs due to a lack of resources. The evidence from speech-therapy highlights the amount of time-on-task required to improve patients' ability to communicate. Naming problems are common and impact on the patients' wellbeing and social inclusion. There is also good evidence that current existing therapeutic approaches work.
A Cochrane review of 39 RCT's involving 2518 participants concluded that speech-therapy results in significant benefits to patients' functional communication. Many of these studies involve high doses of therapy. A meta-analysis examining dose found that positive therapy studies averaged 98 hours of speech therapy in total, while negative studies averaged 43. In the NHS a patient with aphasia can expect a total average of 6-10 hours of SALT. When the intervention takes place or how intensely seems less relevant to recovery. The solution to the lack of available SALT therapy is to produce digital neuro-interventions that give patients the opportunity to practice scientifically validated, impairment based therapy when and where it suits them which gives them access to optimum therapy dose.
Recent improvements in acute stroke care means that demand for already limited NHS resources will increase. Commissioners will need to address this growing unmet need and innovative relatively cheap interventions like this one will provide necessary rehabilitation.
Therapy can be effortful for patients who can sometimes be too fatigued when the therapist comes to do their session. This digital neuro-intervention will provide optimum availability of therapy and therefore place the patient in control of how much they do. The investigators aim to combat this by creating an engaging and adaptive therapy. The adaptiveness will serve to reward the patients for their efforts without ever making them feel like they are failing. This will hopefully boost how long they spend in therapy and therefore make greater gains.
There are therapy 'apps" available for patients with aphasia but the scientific basis for them is lacking and none are targeted for speech production. By using voice recognition software the intervention will be uniquely designed to be used by patients with word retrieval impairments.
What new information will the research provide? The concept of the therapy component is based on standard SALT practice and thus has a strong proof of concept basis, as do the proposed outcome measures. The novel component is packaging it in a user- friendly web-app that is designed for and by people with word-retrieval problems. This is ambitious and yet realistic goal to provide a world-wide evidence-based therapy that can benefit many. This digital neuro-intervention will be in contrast to the plethora of apps available online claiming cognitive training without having scientific proof.
The iTALKbetter research study is a small-scale, randomised, clinical trial for participants with word retrieval impairments post-stroke. The main research question is whether iTALKbetter improves patients' naming ability for trained items. This hypothesis is tested by assessing participants naming abilities on two matched lists of items, half are trained items and half are untrained.
Participants practice with the therapy for set periods of time (therapy block) following a series of (three) baseline measures split over a single, pre-therapy block. The main outcome measure will be a clinically relevant improvement on the naming ability of the trained items (compared to untrained control items).
The investigators also plan to capture brain-based data (structural MRI) in order to test a series of secondary hypotheses relating to both how and why the therapy may work in some participants but not others. All brain imaging will be outside of standard care for the participants and take place at UCL by trained staff.
Hypotheses and Objectives H1-Primary: Does iTB improve naming performance on trained items?
This is a within-subject comparison. The criteria for success is a 10% (raw, or unstandardized) relative improvement in performance. This effect size was used in the recent Big Cactus study.
Primary Objective: Does iTB improve naming performance on trained items?
Secondary Objective(s):
The investigators believe that using this DNI will improve word retrieval on trained items by providing a known therapy used by SLT's through a digital app and by enabling an increased dose of therapy. However, another objective is that by using this DNI and practicing every day, there will be changes in participants' brain structure and in the health of the participants and their carers.
8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.
This study's enrollment of 31 is below the median of 49 across 6,024 interventional studies indexed under Stroke.
Browse Stroke studies →University College, London is the lead sponsor of 651 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There is only one arm (iTalkBetter), but within this arm there are two conditions, trained and untrained items. These are the therapy items (words). Half are trained and half are untrained. Each participant gets a different mix of trained or untrained items. Participants received iTALKbetter therapy for 6 weeks. Participants are required to use the therapy for 1.5 hours everyday to reach the required dose of 60 hours over the 6 week period.
Behavioral: iTalkBetter Trained Items · Behavioral: iTalkBetter Untrained Items
These are the linguistic items to-be-trained
These are the psycholinguistically matched untrained items
Accuracy Performance (%) on a Bespoke Word Retrieval Test: WRT. Two Conditions: 1. Trained Items 2. Untrained Items
The WRT is custom test of word retrieval comprised of a subset of the trained and untrained items form the iTALKbetter therapy. Participants accuracy on the word retrieval test is measured at two timepoints: pre intervention (T3), and post intervention (T4). There are 110 trained and 110 untrained items. Accuracy is reported as a percentage score (min = 0%, max = 100%) for each of the four conditions. The outcome is the percentage change in performance on the WRT. To investigate the efficacy of iTalkBetter in improving the retrieval of trained single words on the WRT, a repeated measures ANOVA was used which compared change in accuracy over the pre-therapy block and the therapy block. There were two factors, each with two levels: time (pre-therapy (Baseline to T3) and therapy (T3 to T4)); and item (trained and untrained lexical items).
Time frame: Two time points: 1. Pre- intervention (T3 = 6 weeks post baseline) 2. Post-intervention (T4 = 12 weeks post baseline)
Qualitative Interviews
Semi-structured interviews were carried out with partcipants to better understand why they took part in the study, and what they hoped to gain (baseline) and then reflections on what it was like taking part in the study (Last time point)
Time frame: Baseline and Post-intervention (T4 = 12 weeks post Baseline)
31 PWA were recruited for the study. Recruitment was from the Predicting Language Outcome and Recovery After Stroke (PLORAS) database and from a local outpatient clinic. Between Sep 7, 2020 and Mar 1, 2022.
| Milestone | iTalkBetter Therapy Group |
|---|---|
| Started | 31 |
| Completed | 27 |
| Not completed | 4 |
| Withdrew: Death | 1 |
| Withdrew: Withdrawal by subject | 3 |
The WRT is custom test of word retrieval comprised of a subset of the trained and untrained items form the iTALKbetter therapy. Participants accuracy on the word retrieval test is measured at two timepoints: pre intervention (T3), and post intervention (T4). There are 110 trained and 110 untrained items. Accuracy is reported as a percentage score (min = 0%, max = 100%) for each of the four conditions. The outcome is the percentage change in performance on the WRT. To investigate the efficacy of iTalkBetter in improving the retrieval of trained single words on the WRT, a repeated measures ANOVA was used which compared change in accuracy over the pre-therapy block and the therapy block. There were two factors, each with two levels: time (pre-therapy (Baseline to T3) and therapy (T3 to T4)); and item (trained and untrained lexical items).
| percentage | iTALKbetter |
|---|---|
| Trained items (T3) | 38.3 ± 0.85 |
| Untrained items (T3) | 38.4 ± 0.95 |
| Trained items (T4) | 50.6 ± 1.8 |
| Untrained items (T4) | 43 ± 1.95 |
Semi-structured interviews were carried out with partcipants to better understand why they took part in the study, and what they hoped to gain (baseline) and then reflections on what it was like taking part in the study (Last time point)
Results for this outcome have not been posted.
Collected over From T1 to T5 (~30 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iTALKbetter | 1/31 (3.2%) | 0/31 (0%) | 0/31 (0%) |
| Age, Continuous(Years) | iTALKbetter |
|---|---|
| Mean | 62 ± 12 |
| Sex: Female, Male(Participants) | iTALKbetter |
|---|---|
| Female | 7 |
| Male | 20 |
| Race and Ethnicity Not Collected(Participants) | iTALKbetter |
|---|
| Word Retrieval Test (WRT)(Percentage) | iTALKbetter |
|---|---|
| Mean | 32 ± 15.77 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Feb 2022, 17 months.
Results were first posted in Mar 2026, 4 years after primary completion.
Of 3,108 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 17 months is below that.
Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.